AstraZeneca

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed.

CEO

Pascal Soriot

CEOPascal Soriot

Employees

94,300

Employees94,300

Headquarters

Cambridge, Cambridgeshire

HeadquartersCambridge, Cambridgeshire

Founded

1913

Founded1913

Employees

94,300

Employees94,300

AZN Key Statistics

Market cap

295.46B

Market cap295.46B

Price-Earnings ratio

31.19

Price-Earnings ratio31.19

Dividend yield

1.62%

Dividend yield1.62%

Average volume

4.20M

Average volume4.20M

High today

$95.74

High today$95.74

Low today

$93.41

Low today$93.41

Open price

$95.14

Open price$95.14

Volume

4.61M

Volume4.61M

52 Week high

$96.51

52 Week high$96.51

52 Week low

$61.24

52 Week low$61.24

AZN News

TipRanks 1h

AstraZeneca Deepens Respiratory Pipeline With New China-Focused Bronchiectasis Study

AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium AstraZeneca (AZN) is sponsoring a new observational stud...

Seeking Alpha 2d

Walmart to replace AstraZeneca on Nasdaq 100 effective Jan. 20

Walmart (WMT) is set to join the Nasdaq-100 Index before the market opens on Jan. 20, 2026, replacing the Anglo-Swedish pharma giant AstraZeneca (AZN), Nasdaq G...

Nasdaq 3d

Walmart To Join Nasdaq-100 Index As AstraZeneca Exits In January 2026 Reshuffle

(RTTNews) - Nasdaq (NDAQ) announced that Walmart Inc. (WMT) will join the Nasdaq-100 Index (NDX), the Nasdaq-100 Equal Weighted Index (NDXE), and the Nasdaq-100...

Analyst ratings

81%

of 32 ratings

Buy

81.3%

Hold

9.4%

Sell

9.4%

More AZN News

TipRanks 3d

AstraZeneca Clears an Early Safety Hurdle With AZD0780–Metformin Interaction Study

AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium AstraZeneca Explores How New Drug AZD0780 Interacts With...

TipRanks 5d

AstraZeneca: Broad Late-Stage Pipeline, Emerging Obesity Franchise, and Autoimmune CAR-T Platform Support Upside and Buy Rating

Analyst Sachin Jain of Bank of America Securities reiterated a Buy rating on AstraZeneca, retaining the price target of p16,500.00. Claim 70% Off TipRanks Premi...

Benzinga 6d

AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial

On Tuesday, AstraZeneca Plc (NASDAQ:AZN) released complete results from the Phase 3 TULIP-SC trial of a subcutaneous (SC) administration of anifrolumab versus p...